



























- 6 and TNF- $\alpha$  and the development of inflammation in obese subjects. *Eur J Med Res* 15: 120-122.
43. Hung J, McQuillan BM, Chapman CM, Thompson PL, Beilby JP (2005) Elevated interleukin-18 levels are associated with the metabolic syndrome independent of obesity and insulin resistance. *Arteriosclerosis, Thrombosis, and Vascular Biology* 25: 1268-1273.
  44. Lukic L, Lalic NM, Rajkovic N, Jotic A, Lalic K, et al. (2014) Hypertension in obese type 2 diabetes patients is associated with increases in insulin resistance and IL-6 cytokine levels: Potential targets for an efficient preventive intervention. *Int J Env Res Pub He* 11: 3586-3598.
  45. Sarbijani HM, Khoshnia M, Marjani A (2016) The association between Metabolic Syndrome and serum levels of lipid peroxidation and interleukin-6 in Gorgan. *Diabetes Metab Syndr* 10: S86-S89.
  46. Kitsios K, Papadopoulou M, Kosta K, Kadoglou N, Chatzidimitriou D, et al. (2012) Interleukin-6, Tumor Necrosis Factor alpha and Metabolic Disorders in Youth. *J Clin Endocrinol Metab* 2: 120-127.
  47. Mojgan M, Mohammad HG, Majid A, Mohammad RM, Mohammad MH (2017) Clinical Significance of Serum IL-6 and TNF- $\alpha$  Levels in Patients with Metabolic Syndrome. *Rep Biochem Mol Biol* 6: 76-79.
  48. Rehman K, Akash MSH, Liaqat A, Kamal S, Qadir MI, et al. (2017) Role of Interleukin-6 in Development of Insulin Resistance and Type 2 Diabetes Mellitus. *Crit Rev Eukaryot Gene Expr* 27: 229-236.
  49. Victoria L, Chanchal L, Shaini L, Abhishek D, Chubalemla L, et al. (2016) Interleukin-6 in obese type II diabetes with hypertension. *Int J Res Med Sci* 4: 896-901.
  50. Gonzalez FZ, Auguet T, Aragones G, Jurado EG, Berlanga A, et al. (2015) Interleukin-17A Gene expression in morbidly obese women. *Int J Mol Sci* 16: 17469-17481.
  51. Bogdan MJ, McDonnell ME, Shin H, Rehman Q, Hasturk H, et al. (2011) Elevated proinflammatory cytokine production by a skewed T cell compartment requires monocytes and promotes inflammation in type 2 diabetes. *J Immunol* 186: 1162-1172.
  52. Dumanovic MS, Stevanovic D, Ljubic A, Jorga J, Simic M, et al. (2009) Increased activity of interleukin-23/interleukin-17 proinflammatory axis in obese women *Int J Obes* 33:151-156.
  53. Lago F, Dieguez C, Reino JG, Gualillo OV (2007) The emerging role of adipokines as mediators of inflammation and immune responses, Cytokine Growth Factor Rev 18: 313-325.
  54. Chen C, Shao Y, Wu X, Huang C, Lu W (2016) Elevated interleukin-17 levels in patients with newly diagnosed Type 2 diabetes mellitus. *Biochem Physiol* 5: 2.
  55. Ohshima K, Mogi M, Jing F, Iwanami J, Tsukuda K, et al. (2012) Roles of interleukin 17 in angiotensin II type 1 receptor-mediated insulin resistance. *Hypertens* 59: 493-499.
  56. Zepp J, Wu L, Li X (2011) IL-17 receptor signaling and T helper 17-mediated autoimmune demyelinating disease. *Trends Immunol* 32: 232-239.
  57. Kern PA, Ranganathan S, Li C, Wood L, Ranganathan G (2001) Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. *Am J Physiol Endocrinol Metab* 280: E745-E751.
  58. Ghanshyam G, Yogita S, Rajkumar V, Gajanand J (2018) Association of adipokines with metabolic syndrome in North-West Rajasthan (India). *Am J Biochem* 8: 45-55.
  59. Gahlot G, Soni Y, Joshi G, Vyas RK, Agarwal RP (2020) Evidences for IL-6, IL-23, IL-17 and Adipokines in Patients with Metabolic Syndrome and Type 2 Diabetes Immunopathogenesis. *Adv Nanomed Nanotechnol Res* 2: 112-121.